tailieunhanh - Hepatocellular carcinoma (HCC): A global perspective

Document presentation of content: Global prevalence and incidence, HCC risk factors, primary care, cascades—a resource-sensitive approach, primary HCC prevention, secondary HCC prevention—surveillance, secondary HCC prevention—surveillance, tertiary HCC prevention—recurrence. | WGO Global Guideline HCC 1 World Gastroenterology Organisation Global Guideline Hepatocellular carcinoma HCC a global perspective November 2009 Review team Peter Ferenci chair Austria Michael Fried Switzerland Douglas Labrecque USA J. Bruix Spain M. Sherman Canada M. Omata Japan J. Heathcote Canada T. Piratsivuth Thailand Mike Kew South Africa Jesse A. Otegbayo Nigeria . Zheng China S. Sarin India S. Hamid Pakistan Salma Barakat Modawi Sudan Wolfgang Fleig Germany Suliman Fedail Sudan Alan Thomson Canada Aamir Khan Pakistan Peter Malfertheiner Germany George Lau Hong Kong . Carillo Brazil Justus Krabshuis France Anton Le Mair The Netherlands World Gastroenterology Organisation 2009 WGO Global Guideline HCC 2 Contents 1 Introduction 2 Minimal resources 3 Medium resources 4 High resources World Gastroenterology Organisation 2009 WGO Global Guideline HCC 3 1 Introduction More than 600 000 people die from hepatocellular carcinoma HCC each year. Worldwide research on the disease needs to be intensified in both the medical and pharmaceutical fields especially with a focus on providing help to areas where resources are limited. Treatment approaches depend on the stage of the disease at diagnosis and on access to complex treatment regimens. However advanced disease is not curable and management of advanced disease is expensive and only marginally effective in increasing quality-adjusted life-years. The delivery of health-care services for HCC can be improved by developing centers of excellence. Concentrating medical care in this way can lead to an increased level of expertise so that resections are performed by surgeons who understand liver disease and the limitations of resection and other relevant procedures. Promising new agents are beyond the reach of those who would benefit most in low-resource countries sorafenib is out of the question for general use. For example snapshot cost indications of monthly pharmacy prices for sorafenib are 7300 in China 5400 in the .